— Know what they know.
Not Investment Advice

INMB

INmune Bio, Inc.
1W: -1.6% 1M: -9.0% 3M: -35.1% YTD: -20.8% 1Y: -85.3% 3Y: -80.3% 5Y: -91.5%
$1.22
-0.01 (-0.41%)
 
NASDAQ · Healthcare · Biotechnology · $32.4M · Alpha Radar Sell · Power 37
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$32.4M
52W Range1.16-11.64
Volume222,575
Avg Volume440,888
Beta0.85
Dividend
Analyst Ratings
6 Buy 2 Hold 1 Sell
Consensus Buy
Company Info
CEODavid J. Moss
Employees13
SectorHealthcare
IndustryBiotechnology
IPO Date2019-02-04
225 NE Mizner Boulevard
Boca Raton, FL 33432
US
858 964 3720
About INmune Bio, Inc.

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Recent Insider Trades

NameTypeSharesPriceDate
Ganjei James Kelly A-Award 150,000 $1.48 2025-12-01
ALLEN MARCIA A-Award 150,000 $1.48 2025-12-01
Moss David J A-Award 750,000 $1.48 2025-12-01
Lowdell Mark William A-Award 600,000 $1.48 2025-12-01
Ellspermann Cory Ran A-Award 300,000 $1.48 2025-12-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms